ethyl 1-oxido-1-[[2-[3-(trifluoromethyl)phenyl]phenyl]methyl]-4H-1,5-naphthyridin-1-ium-3-carboxylate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 1-oxido-1-[[2-[3-(trifluoromethyl)phenyl]phenyl]methyl]-4H-1,5-naphthyridin-1-ium-3-carboxylate
• 化学式: C25H21F3N2O3
• 分子量: 454.4
• InChiKey: BDMDZGKBZDGSHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  57.3
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE
  申请人：Savira pharmaceuticals GmbH

  公开号：US20160039818A1

  公开（公告）日：2016-02-11

  The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

  本发明涉及一种具有通式（V）的化合物，可选地为药物可接受的盐、溶剂合物、多晶形、共药、共晶体、前药、互变异构体、外消旋体、对映体或其混合物，这些化合物在治疗、改善或预防病毒性疾病方面具有用途。此外，还公开了特定的联合治疗方法。
• Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease
  申请人：Savira pharmaceuticals GmbH

  公开号：US20170290834A1

  公开（公告）日：2017-10-12

  The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
• US9505758B2
  申请人：——

  公开号：US9505758B2

  公开（公告）日：2016-11-29
• [EN] NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE<br/>[FR] DÉRIVÉS DE NAPHTHYRIDINONE ET LEUR UTILISATION POUR LE TRAITEMENT, LE SOULAGEMENT OU LA PRÉVENTION D'UNE MALADIE VIRALE
  申请人：SAVIRA PHARMACEUTICALS GMBH

  公开号：WO2014108408A1

  公开（公告）日：2014-07-17

  The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.